UNITED THERAPEUTICS CORP (UTHR) Stock Fundamental Analysis
USA - NASDAQ:UTHR - US91307C1027 - Common Stock
447.45 USD
+10.12 (+2.31%)
447.45 USD
0 (0%)
Overall UTHR gets a fundamental rating of 7 out of 10. We evaluated UTHR against 534 industry peers in the Biotechnology industry. UTHR gets an excellent profitability rating and is at the same time showing great financial health properties. A decent growth rate in combination with a cheap valuation! Better keep an eye on UTHR. With these ratings, UTHR could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
UTHR had positive earnings in the past year.
UTHR had a positive operating cash flow in the past year.
UTHR had positive earnings in each of the past 5 years.
Each year in the past 5 years UTHR had a positive operating cash flow.
1.2 Ratios
UTHR has a better Return On Assets (17.30%) than 96.07% of its industry peers.
The Return On Equity of UTHR (19.30%) is better than 95.51% of its industry peers.
UTHR has a better Return On Invested Capital (17.33%) than 96.82% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for UTHR is in line with the industry average of 15.38%.
The last Return On Invested Capital (17.33%) for UTHR is above the 3 year average (14.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROIC | 17.33% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
1.3 Margins
UTHR has a better Profit Margin (40.65%) than 98.13% of its industry peers.
UTHR's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 48.65%, UTHR belongs to the best of the industry, outperforming 99.44% of the companies in the same industry.
UTHR's Operating Margin has improved in the last couple of years.
UTHR's Gross Margin of 88.59% is amongst the best of the industry. UTHR outperforms 90.07% of its industry peers.
UTHR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% |
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so UTHR is creating value.
Compared to 1 year ago, UTHR has less shares outstanding
The number of shares outstanding for UTHR has been increased compared to 5 years ago.
The debt/assets ratio for UTHR has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 18.75 indicates that UTHR is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 18.75, UTHR belongs to the best of the industry, outperforming 89.33% of the companies in the same industry.
UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 18.75 |
ROIC/WACC1.99
WACC8.71%
2.3 Liquidity
UTHR has a Current Ratio of 6.40. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
UTHR has a Current ratio of 6.40. This is in the better half of the industry: UTHR outperforms 66.67% of its industry peers.
A Quick Ratio of 6.07 indicates that UTHR has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.07, UTHR is doing good in the industry, outperforming 64.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 15.90% over the past year.
The Earnings Per Share has been growing by 16.88% on average over the past years. This is quite good.
The Revenue has grown by 13.50% in the past year. This is quite good.
The Revenue has been growing by 14.71% on average over the past years. This is quite good.
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
3.2 Future
The Earnings Per Share is expected to grow by 11.57% on average over the next years. This is quite good.
Based on estimates for the next years, UTHR will show a quite strong growth in Revenue. The Revenue will grow by 11.21% on average per year.
EPS Next Y14.15%
EPS Next 2Y9.73%
EPS Next 3Y7.6%
EPS Next 5Y11.57%
Revenue Next Year11.56%
Revenue Next 2Y8.55%
Revenue Next 3Y8.2%
Revenue Next 5Y11.21%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
UTHR is valuated correctly with a Price/Earnings ratio of 16.96.
Based on the Price/Earnings ratio, UTHR is valued cheaply inside the industry as 95.69% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.03. UTHR is valued slightly cheaper when compared to this.
UTHR is valuated correctly with a Price/Forward Earnings ratio of 15.11.
Compared to the rest of the industry, the Price/Forward Earnings ratio of UTHR indicates a rather cheap valuation: UTHR is cheaper than 95.32% of the companies listed in the same industry.
UTHR is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.27, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.96 | ||
| Fwd PE | 15.11 |
4.2 Price Multiples
UTHR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. UTHR is cheaper than 96.82% of the companies in the same industry.
95.51% of the companies in the same industry are more expensive than UTHR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.13 | ||
| EV/EBITDA | 9.71 |
4.3 Compensation for Growth
UTHR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of UTHR may justify a higher PE ratio.
PEG (NY)1.2
PEG (5Y)1
EPS Next 2Y9.73%
EPS Next 3Y7.6%
5. Dividend
5.1 Amount
UTHR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
447.45
+10.12 (+2.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.47%
Inst Owner Change-1.79%
Ins Owners1.76%
Ins Owner Change4.02%
Market Cap20.24B
Revenue(TTM)3.13B
Net Income(TTM)1.27B
Analysts80.91
Price Target499.6 (11.65%)
Short Float %4.58%
Short Ratio2.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.9%
Min EPS beat(2)-9.46%
Max EPS beat(2)-2.35%
EPS beat(4)0
Avg EPS beat(4)-4.02%
Min EPS beat(4)-9.46%
Max EPS beat(4)-0.45%
EPS beat(8)2
Avg EPS beat(8)-2.47%
EPS beat(12)5
Avg EPS beat(12)-3.15%
EPS beat(16)7
Avg EPS beat(16)-2.98%
Revenue beat(2)0
Avg Revenue beat(2)-3.23%
Min Revenue beat(2)-3.81%
Max Revenue beat(2)-2.65%
Revenue beat(4)1
Avg Revenue beat(4)-0.39%
Min Revenue beat(4)-3.81%
Max Revenue beat(4)6.71%
Revenue beat(8)5
Avg Revenue beat(8)1.56%
Revenue beat(12)7
Avg Revenue beat(12)1.27%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)5.67%
PT rev (3m)28.58%
EPS NQ rev (1m)-0.78%
EPS NQ rev (3m)2.99%
EPS NY rev (1m)0.07%
EPS NY rev (3m)-1.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.33%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)-0.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.96 | ||
| Fwd PE | 15.11 | ||
| P/S | 6.47 | ||
| P/FCF | 18.13 | ||
| P/OCF | 13 | ||
| P/B | 3.07 | ||
| P/tB | 3.13 | ||
| EV/EBITDA | 9.71 |
EPS(TTM)26.39
EY5.9%
EPS(NY)29.62
Fwd EY6.62%
FCF(TTM)24.68
FCFY5.52%
OCF(TTM)34.41
OCFY7.69%
SpS69.17
BVpS145.7
TBVpS143.12
PEG (NY)1.2
PEG (5Y)1
Graham Number294.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROCE | 22.37% | ||
| ROIC | 17.33% | ||
| ROICexc | 29.21% | ||
| ROICexgc | 30.07% | ||
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% | ||
| FCFM | 35.69% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexgc growth 3Y23.22%
ROICexgc growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 533.09% | ||
| Cap/Sales | 14.06% | ||
| Interest Coverage | 81.39 | ||
| Cash Conversion | 96.99% | ||
| Profit Quality | 87.79% | ||
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 | ||
| Altman-Z | 18.75 |
F-Score8
WACC8.71%
ROIC/WACC1.99
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
EPS Next Y14.15%
EPS Next 2Y9.73%
EPS Next 3Y7.6%
EPS Next 5Y11.57%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
Revenue Next Year11.56%
Revenue Next 2Y8.55%
Revenue Next 3Y8.2%
Revenue Next 5Y11.21%
EBIT growth 1Y12.9%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year18.1%
EBIT Next 3Y5.05%
EBIT Next 5Y-4.6%
FCF growth 1Y46.07%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y62.87%
OCF growth 3Y30.42%
OCF growth 5YN/A
UNITED THERAPEUTICS CORP / UTHR FAQ
What is the fundamental rating for UTHR stock?
ChartMill assigns a fundamental rating of 7 / 10 to UTHR.
Can you provide the valuation status for UNITED THERAPEUTICS CORP?
ChartMill assigns a valuation rating of 7 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Undervalued.
What is the profitability of UTHR stock?
UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for UTHR stock?
The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 16.96 and the Price/Book (PB) ratio is 3.07.
What is the financial health of UNITED THERAPEUTICS CORP (UTHR) stock?
The financial health rating of UNITED THERAPEUTICS CORP (UTHR) is 9 / 10.